MedTrace Logo

A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer

NCT05179239 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2025-04-15

No results posted yet for this study

Summary

The study is being conducted to evaluate the efficacy, and safety of SHR-1701 or Placebo Plus Chemotherapy With or Without BP102 (Bevacizumab) as First-Line Treatment in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer.

Conditions

Interventions

DRUG

SHR-1701 + paclitaxel + cisplatin/carboplatin + BP102

SHR-1701 + paclitaxel + cisplatin/carboplatin + BP102

DRUG

SHR-1701 + paclitaxel + cisplatin/carboplatin± BP102

SHR-1701 + paclitaxel + cisplatin/carboplatin± BP102

DRUG

Placebo + paclitaxel + cisplatin/carboplatin ± BP102

Placebo + paclitaxel + cisplatin/carboplatin ± BP102

Sponsors & Collaborators

  • Suzhou Suncadia Biopharmaceuticals Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-26
Primary Completion
2024-08-12
Completion
2024-08-12

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05179239 on ClinicalTrials.gov